Phaseline

Companies › Astria Therapeutics

Astria Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Other, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
navenibart–Phase 3Hereditary Angioedema (HAE); Healthy Adult ParticipantsDec 2026
STAR-0215–Phase 2Hereditary AngioedemaMar 2031
STAR-0310–Phase 1Healthy Participants–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06782477STAR-0310Phase 1Healthy ParticipantsOtherJan 2026
NCT06842823navenibartPhase 3Hereditary Angioedema (HAE)ImmunologyDec 2026
NCT07635095navenibartPhase 1Healthy Adult ParticipantsOtherDec 2026
NCT06007677STAR-0215Phase 2Hereditary AngioedemaImmunologyMar 2031

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Mirador Therapeutics Daewon Pharmaceutical Accro Bioscience (Suzhou) Clarent Biopharma Zhejiang Wenda Pharma Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.